TG Therapeutics (TGTX)

TG Therapeutics (TGTX) will present data from the Phase 2 trial of TG-1101 (ublituximab) in relapsing forms of Multiple Sclerosis at the upcoming 7th Joint ECTRIMS -- ACTRIMS meeting, to be held from October 25 -- 28, 2017. These data presentations support the recently announced international Phase 3 program evaluating TG-1101 (ublituximab) for the treatment of relapsing form of Multiple Sclerosis. These trials are expected to commence before the end of Q3 2017.